2016-Jun-25

10th Annual General Meeting
of MetrioPharm AG

 

The 10th Annual General Meeting of MetrioPharm AG was held at the Priora Business Center in Kloten (Zurich).

70'521'884 shares of the CHF 19'140'000.00 capital stock subdivided into 95'700'000 ordinary registered shares with a nominal value of CHF 0.20 were present. A total of 40 shareholders of MetrioPharm AG attended the AGM – 22 shareholders were personally present and 18 shareholders attended through proxy.

At the beginning, the Management and Board of MetrioPharm AG presented the 2015 annual financial statement and the progress of MetrioPharm's Research and Development projects. After the discharge of the Board of Directors three new members were voted into the Board. The Annual General Meeting elected, in addition to Dr. Werner Wolf and Markus Wenner (whose terms are still running for three more years), Ekkehard Brysch, David Davis, and Dr. Sylvie Grégoire to the Board of Directors. Dr. Sylvie Grégoire has more than 28 years of experience in the international biotech and pharma industry and replaces Dr. Wolfgang Brysch as executive President of the Board. Dr. Brysch had offered his position for election in order to concentrate more on the operative business and the Research and Development projects in his new position as CEO of MetrioPharm AG.

You can find the voting results and the presentation to the 10th Annual General Meeting on our website under https://metriopharm.de/en/investors/en_downloads.

Current Status of MP1032's Phase IIa in Psoriasis

MetrioPharm AG started with the first patient dosing in the phase IIa clinical trial of MP1032 in moderate-to-severe psoriasis on May 24, 2016. After successful enrolment of nine patients at the main study site in Berlin, another site in Dresden, Germany, was opened on June 28, 2016.

An enrolment of a total of 44 male and female participants with chronic plaque psoriasis is planned in this clinical trial. Primary endpoints of the study include pharmacokinetics and safety and tolerability of multiple doses of MP1032 over six weeks in patients. Preliminary evidence of effectiveness is examined as a secondary endpoint.

More information about this phase IIa clinical trial is available under the search term MetrioPharm at https://www.clinicaltrialsregister.eu/ctr-search/search.